New Delhi: Researchers are constantly trying to prevent and deal with the growing Coronavirus in the country. Vaccination of two indigenous Corona Vaccine is also going on. People are being given their two doses. Important research has been done before the start of the third phase of the Vaccination campaign from 1 May. Under this, 7 people in Chennai have been given the third dose of Corona Vaccine Covaxin on Monday. It is being called a booster dose. This was done to see if it could develop immunity in the person’s body for a long time.
According to the Times of India report, 7 people have been given the third dose of covaxin at SRM Medical College Hospital and Research Center, Chennai. He was given the second dose of vaccine 6 months ago. Under this research, a total of 190 people are to be given the third dose of vaccine in 8 centers in cities like New Delhi, Patna and Hyderabad. Out of these, about 20 to 25 people will take this dose in SRM itself.
Covaxin has been formed by Hyderabad-based company Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology. According to Dr. Satyajit Mohapatra, the principal researcher of this research in the hospital, all the people involved in the research are between 18 and 55 years old. These will be monitored for the next 6 months. Blood samples will be taken after one month, three months, and 6 months of all these people. After this, the immunity capacity will be tested.
On April 2, the expert committee of drug regulator DCGI approved Bharat Biotech to give the third dose of covaxine to some volunteers in the clinical trial of the Covid-19 vaccine. Bharat Biotech submitted a revised report to the Subject Expert Committee (SECG) of the Drug Controller General of India (SECG) on the second phase of clinical trials to deliver booster doses six months after the second dose.
The SEC had said, “The company has reported to amend the Phase II clinical trial approved for giving booster dose six months after the second dose. After detailed deliberations, the committee recommended that the company be allowed to give six micrograms in the booster dose and that the trial should be considered for six months after the third dose. ‘
